Trial Profile
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Sirolimus (Primary) ; Filgrastim
- Indications Beta-thalassaemia; Graft-versus-host disease; Sickle cell anaemia
- Focus Therapeutic Use
- 27 Feb 2024 Planned End Date changed from 20 Jan 2024 to 31 Jan 2026.
- 27 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2023 Planned End Date changed from 1 Feb 2024 to 20 Jan 2024.